Study to Evaluate Safety & Tolerability of BMS-906024 in Combination With Chemotherapy & to Define DLTs & MTD of BMS-906024 in Combination With One of the Following Chemotherapy Regimens; Weekly Paclitaxel, 5FU+Irinotecan or Carboplatin+Paclitaxel i

• Status: Completed
• Trial end date: 2017-05-08
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to identify a safe and tolerable dose of BMS-906024 in combination with each of the following three chemotherapy regimens: Paclitaxel, 5FU plus Irinotecan (FOLFIRI), or Carboplatin plus Paclitaxel in subjects with advanced or metastatic solid tumors

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bristol-Myers Squibb
• Treatments: Albumin-Bound Paclitaxel; Camptothecin; Carboplatin; Fluorouracil; Irinotecan; Leucovorin; Paclitaxel

Criteria

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com.

Inclusion Criteria:

• Subjects with advanced or metastatic solid tumors for whom a chemotherapy regimen is considered appropriate

• Subjects with non-small cell lung cancer and triple-negative breast cancer are preferred

• Biopsy accessible tumor (may use archived tumor samples under certain circumstances)

• Life expectancy of at least 3 months

• Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1

• Measurable disease

Exclusion Criteria:

• Uncontrolled brain metastases

• Infection

• Gastrointestinal (GI) disease with increased risk of diarrhea (e.g. inflammatory bowel disease)

• Uncontrolled or significant cardiovascular disease

• Subjects taking medications known to increase risk of Torsades de Pointes